No increased risk of severe COVID-19 in asthma treated with biologics

Beyaz S., Erecan E., MUTLU P., ÖZŞEKER Z. F.

EURASIAN JOURNAL OF PULMONOLOGY, vol.24, no.2, pp.85-94, 2022 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.14744/ejp.2022.9821
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.85-94
  • Keywords: Asthma, biologic agents, COVID-19, dupilumab, mepolizumab, omalizumab, INFECTION, DISEASE, THERAPY, PATIENT, TMPRSS2, PEOPLE, ACE2
  • Çanakkale Onsekiz Mart University Affiliated: Yes


BACKGROUND AND AIM: Biologics can be used safely for patients with severe asthma during the coronavirus pandemic, but there is still a lack of information regarding their effects during SARS-CoV-2 infection. The aim of this study was to evaluate the impact of biologic therapies on the course of SARS-CoV-2 infection and to assess the outcome of COVID-19 for severe asthmatics in pandemic conditions.